The value and role of non-invasive prenatal testing in a select South African population

South African Medical Journal

Volumn 106, Issue 10, 2016, Pages 1047-1050

  Mnyani, C N ^a   Nicolaou, E ^a,b   Bister, S ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b Maternal Fetal Medicine Centre Morningside MediClinic   (South Africa)

Author keywords

Cell free DNA; CfDNA; NIPT; Non invasive prenatal testing

Indexed keywords

ADULT; ARTICLE; CHROMOSOME ABERRATION; FEMALE; FETUS KARYOTYPING; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; NON INVASIVE PRENATAL TESTING; PREGNANCY OUTCOME; PRENATAL SCREENING; RETROSPECTIVE STUDY; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; SOUTH AFRICA; TRIPLOIDY; TRISOMY 13; TRISOMY 18; TRISOMY 21;

EID: 84989829858     PISSN: 02569574     EISSN: 20785135     Source Type: Journal    
DOI: 10.7196/SAMJ.2016.v106i10.10650     Document Type: Article

References (14)

1. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: Ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992;304(6831):867-869. DOI:10.1136bmj.304.6831.867
2. Snijders RJM, Johnson S, Sebire NJ, Noble PL, Nicolaides KH. First-trimester ultrasound screening for chromosomal defects. Ultrasound Obstet Gynecol 1996;7(3):216-226. DOI:10.1046/j.1469-0705.1996.07030216.x
3. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down’s syndrome based on tests performed during the first and second trimesters. N Engl J Med 1999;341(7):461-467. DOI:10.1056/ NEJM199908123410701
4. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350(9076):485-487. DOI:10.10.1016/S0140-6736(97)02174-0
5. Benn P, Cuckle H, Pergament E. Non-invasive prenatal testing for aneuploidy: Current status and future prospects. Ultrasound Obstet Gynecol 2013;42(1):15-33. DOI:10.1002/uog.12513
6. Poon LC, Musci T, Song K, et al. Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks’ gestation: Relation to fetal and maternal characteristics and pregnancy outcomes. Fetal Diagn Ther 2013;33(4):215-223. DOI:10.1159/000346806
7. Martin A, Krishna I, Martina B, et al. Can the quantity of cell-free fetal DNA predict preeclampsia: A systematic review. Prenat Diagn 2014;34(7):685-691. DOI:10.1002/pd.4416
8. Rolnik DL, O’Gorman N, Fiolna M, et al. Maternal plasma cell-free DNA in the prediction of preeclampsia. Ultrasound Obstet Gynecol 2015;45(1):106-111. DOI:10.1002/uog.14671
9. Royal College of Obstetricians and Gynaecologists. Non-invasive Prenatal Testing for Chromosomal Abnormality using Maternal Plasma DNA. Scientific Impact Paper No. 15. London: RCOG, 2014.
10. Thilaganathan B. Ushering in a new dawn in obstetrics and gynecology: The industry of cell-free DNA testing. Ultrasound Obstet Gynecol 2015;45(1):1-3. DOI:10.1002/uog.14744
11. Gregg AR, Gross SJ, Best RG, et al, for the Noninvasive Prenatal Screening Work Group of the American College of Medical Genetics and Genomics. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med 2013;15(5):395-398. DOI:10.1038/gim.2013.29
12. Salomon LJ, Alfirevic Z, Audibert F, et al. ISUOG consensus statement on the impact of non-invasive prenatal testing (NIPT) on prenatal ultrasound practice. Ultrasound Obstet Gynecol 2014;44(1):122-123. DOI:10.1002/uog.13393
13. American College of Obstetricians and Gynecologists. Cell-free DNA screening for fetal aneuploidy. Committee Opinion No. 640. Obstet Gynecol 2015;126(3):e31-e37. DOI:10.1097/ AOG.0000000000001051
14. Harris PA, Taylor R, Thielke R, Payne J, Conde JG. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42(2):377-381. DOI:10.1016/j.jbl.2008.08.010